Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OsteoRemedies has commercialized the first FDA-cleared modular spacer system for both hip and knee two-stage infection revision arthroplasty. Their REMEDY Spacer System and SPECTRUM GV Hip Spacer/Bone Cement are indicated for temporary use in patients with prosthetic joint infections. Clinical data highlight their effectiveness in delivering local antibiotics to combat biofilm formation during staged revisions.[2][4] The company claims a significant share of the U.S. market for these devices (~20% as of recent reports).[2] No clinical trial pipeline; all products are cleared medical devices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OsteoRemedies.